Great News: A New Journal Rare Disease and Orphan Drugs Journal Led by Professor Daniel Scherman Officially Released Online

Published on: 7 Apr 2021 Viewed: 622

In March 2021, OAE formally announced the appointment of Professor Daniel Scherman as the Editor-in-Chief of the new journal Rare Disease and Orphan Drugs Journal (www.rdodjournal.com, RDODJ).





Editor-in-Chief   Professor Daniel Scherman

Professor Daniel Scherman is presently emeritus "excellence scientist" at the French National Centre for Scientific Research (CNRS), France, Director of the Rare Disease Foundation, France, Head of Medicine and Life Sciences Division of the European Academy of Sciences EURASC, and corresponding member of the French National Academy of Pharmacy.

His main research interests focus on gene therapy, drug delivery, drug discovery and bioimaging of rare disease. As of the beginning of 2021, he has published over 514 publications (Web of Science, H-index of 67, more than 21, 000 citations), 54 book Chapters, and 40 independent patent applications. Professor Scherman also has rich experience in journal management. He was the Editor in the series "Advances in Behavioral Biology" and is presently the Editor of "Handbook of Gene Therapy and Genetic Pharmacology".

Professor Scherman has received numerous recognitions such as the Great Prize Émilia Valori of the French Academy of Sciences, the Neurobiology Prize of the French National Academy of Medicine, the CNRS Silver Medal, and the Academic Palms.

RDODJ will report scientific advances in the genetics of rare disease, the molecular basis of pathologies, and translational research on diagnosis, prevention and treatment. In addition, RDODJ aims to provide a forum for scientific studies and discussion covering the important regulatory, socio-economic and human sciences issues related to rare disease and orphan drugs.

In his new role, Professor Scherman stated "The ultimate objective of RDODJ is to promote the dissemination of research results and scientific achievements among the research community, practitioners, and patient-advocacy organizations.".

OAE is confident that under Professor Scherman's leadership, RDODJ will be a great success that will benefit authors, readers and ultimately those whose lives will get improved through the important research published in the journal.

We would like to extend our sincere welcome to Professor Scherman for serving as this new exciting role.